NR4A1 and breast cancer: DMBA-NMU administration induced aggressive hormone receptor-positive BC, elevating ER (∼26-fold) and PR (∼12-fold), with strong upregulation of PI3K (+21-fold), Akt (+9-fold), mTOR (+7-fold), Ras (+34-fold), MAPK (+45-fold), MDM2 (+13-fold), and PDK1 (+39-fold).